ClinicalTrials.gg
DrugBiological

Oleclumab clinical trials

Also written MEDI9447.

studies test it
17
open now
3
in phase 3
1
first study started
2017

How each study uses oleclumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the oleclumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Oleclumab
14
Anti-CD73 Monoclonal Antibody MEDI9447
3

Development codes

MEDI9447
8

Studies by the year they started

17 studies that test it; most in 2018 (4)

Studies that test oleclumab, by start year
YearStudies
20171
20184
20193
20201
20213
20222
20231
20241
20261

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
14
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 7 · Other 10

AstraZeneca (5) · University Health Network, Toronto (3) · M.D. Anderson Cancer Center (2) · Jules Bordet Institute (2) · MedImmune LLC (2) · Assistance Publique Hopitaux De Marseille (1) · National Cancer Institute (NCI) (1) · Montefiore Medical Center (1)

Often tested with

Tested in the same studies.

Monalizumab (6) · Durvalumab (2) · Ceralasertib (2) · Danvatirsen (1) · Vistusertib (1) · Olaparib (1) · Trastuzumab deruxtecan (1) · Cediranib (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3, 1 in phase 3

Studies that test oleclumab, phase 3 first.

Studies

Open first, then newest update. How each study uses oleclumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 17

Given beside what is tested · 10 — oleclumab is usual care or a partner of the new treatment

Codes

What other systems call oleclumab · ClinicalTrials.gg INT015060

  • UNII (FDA) 5CRY01URYQOLECLUMABConfirmed FDA, Wikidata
  • Wikidata Q47123037oleclumabConfirmed FDA, Wikidata
  • NCI Thesaurus C123914OleclumabOne source FDA
  • DrugBank DB15088One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.